Session: Immune Responses to GT/Therapeutics

Preclinical and Clinical Development of Tolerogenic Immtor Nanoparticles to Mitigate Immunogenicity of Biologic and Gene Therapies

Wednesday, June 19, 2024

1:40 PM – 2:05 PM PT

Location: Salon 7

Speaker(s)

Kei Kishimoto, PhD

former CSO
Selecta Biosciences
Lexington, Massachusetts, United States

Disclosure(s):

Kei Kishimoto, PhD: No relevant disclosure to display

How development of anti-drug antibodies (ADAs) is a common cause for treatment failure and adverse events associated with biologic therapies
How ImmTOR tolerogenic nanoparticles were developed and validated in animal models and in humans
Challenges and lessons learned